Replies to post #97037 on Biotech Values

[mcbio]

Re: IDX320

Is it noteworthy that they are only dosing QD or was it known beforehand? I find it interesting they aren't even bothering with a BID dose.

It's a 3rd gen PI, so I think the expectations have been for awhile for QD dosing with the drug with the exception of genotype 3 HCV patients (#msg-50686434 ).

[DewDiligence]

Re: IDX320 dosing regimen

Following up on mcbio’s reply in #msg-51128566, I noticed in the slide set of today’s Jefferies webcast that IDX320 has a half-life in humans of 26 hours, which is about 3x the half-life that was seen in monkeys. Thus, qD doing of IDX320 is assured except in genotype-3a, where IDX320 has weaker antiviral activity than in other genotypes.

The planned BID dosing of IDX320 in gentotype-3a is not mandated by the PK; rather, it is simply a way for IDIX to double the cumulative daily dose without having to develop a separate tablet just for this genotype.